Indivior PLC is a global healthcare company focused primarily on the treatment of addiction and serious mental health conditions
It specializes in developing and commercializing innovative pharmaceutical products designed to support individuals struggling with substance use disorders, particularly opioid addiction. The company's portfolio includes medications that facilitate recovery by reducing cravings and withdrawal symptoms, thereby helping patients manage their addiction effectively. Indivior is committed to advancing research and development in this field, aiming to improve patient outcomes and support the global effort to combat addiction through comprehensive treatment solutions.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Indivior's 2025 outlook missed estimates, citing Suboxone sales erosion. The company plans $100 million in cost cuts, with $50M reinvested in Sublocade.
Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatment. Addex could receive up to $330 million plus royalties under the agreement, while advancing its own GABAB PAM program for chronic cough.
Indivior lowers its profit forecast for 2024, discontinues sales of its schizophrenia drug Perseris, and announces job cuts, causing shares to plummet nearly 38%. The company updates its financial guidance and settles litigation for $85 million.
